Mairs & Power Inc
IDXG

Mairs & Power Inc’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Mairs & Power Inc’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,000
Closed -$40K – 229
2019
Q3 		$40K Buy
+5,000
New +$39K ﹤0.01% 212

Other funds holding IDXG

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Mairs & Power Inc's IDXG Position: Q4 2019 in Review

Mairs & Power Inc sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2019, closing a stake of 5,000 shares — an estimated $40K sold.

Mairs & Power Inc first reported a position in IDXG in Q3 2019 and held it in 1 quarter. The position peaked at $40K in Q3 2019. 17 funds tracked by Wall St. Rank hold IDXG as of Q4 2019.

  • Mairs & Power Inc reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Mairs & Power Inc sold 5,000 Interpace Biosciences, Inc. Common Stock shares in Q4 2019, an estimated $40K.
  • Mairs & Power Inc first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Mairs & Power Inc's Interpace Biosciences, Inc. Common Stock position peaked at $40K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2019.

Based on Mairs & Power Inc's 13F filing for Q4 2019, filed 14 Feb 2020.